Kellogg School

Wisr AI Announces Addition of Thomas Bain to Advisory Board

Retrieved on: 
Mittwoch, August 2, 2023
Growth capital, IBM, Executive, University of Massachusetts Boston, University, Securin, Senior, Public affairs, National Security Innovation Network, Communication, OWASP, Intelligence, Kellogg School, Trustwave Holdings, HIMSS, ABM, Marketing, Certification, Content marketing, Organization, Machine, Market research, Application security, Wisr, Acquisition, Trend Micro, Application, Mastercard, SecurityScorecard, Rhode Island College, Digital marketing, Northwestern University, AR, Automation, Medical device, Sophos, Science

Mr. Bain has over 15 years of experience driving the marketing and go-to-market efforts for leading high-growth cybersecurity companies, including Cyware and RiskRecon (acquired by Mastercard).

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Wisr AI Solutions Inc. ("Wisr AI" or the "Company"), a leading AI-driven cybersecurity platform provider, is pleased to announce the addition of Thomas Bain to the Company's Advisory Board.
  • Mr. Bain currently serves as the Executive Vice President of Marketing for Finite State .
  • Prior to that, Mr. Bain served as the Senior Vice President of Marketing at RiskRecon , before the company was acquired by Mastercard.
  • "We are excited to welcome Mr. Bain, a seasoned cybersecurity veteran, to Wisr AI's Advisory Board," said Rob Goehring, CEO and founder of Wisr AI.

VEON appoints Faisal Ghori Group Director Investor Relations

Retrieved on: 
Montag, Juli 31, 2023
University, MBA, Kellogg School, Investment, Berkeley, Euronext Amsterdam, University of California, Berkeley, VEON, Growth, Northwestern University, BA, Cryptocurrency, Research

Amsterdam, 31 July 2023 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, today announces that Faisal Ghori has been appointed as its new Group Director Investor Relations.

Key Points: 
  • Amsterdam, 31 July 2023 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, today announces that Faisal Ghori has been appointed as its new Group Director Investor Relations.
  • Faisal Ghori will join VEON effective August 1st, based in Dubai, and will report to the VEON Group CFO Joop Brakenhoff.
  • As VEON accelerates its growth, meeting the increased demand of digitalization in the emerging economies, Faisal will enhance the Group’s engagement with current and potential new investors from around the world, leading VEON’s Investor Relations team.
  • I welcome Faisal to the role of Group Director Investor Relations at this exciting time, and look forward to working with our IR team, effectively communicating this opportunity to the global investor community.

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

Retrieved on: 
Donnerstag, Juli 27, 2023
EUA, Prader–Willi syndrome, Portfolio manager, SVKM's NMIMS, Drug development, University, AbbVie, Abbott Laboratories, COVID-19, Kellogg School, Antibody, Northfield Laboratories, M.B.A, UBS, Immunodeficiency, Notre Dame, Northwestern University, Pharmaceutical industry

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors.

Key Points: 
  • WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors.
  • Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development.
  • Cotter’s comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital markets expertise, make her an excellent addition to our board of directors,” said Dave Hering, Chief Executive Officer of Invivyd.
  • Ms. Cotter received an M.B.A from the Kellogg School of Management at Northwestern University and a B.S.

Sleep Number Appoints Francis Lee to Executive Vice President and Chief Financial Officer

Retrieved on: 
Donnerstag, Juli 27, 2023
Online Retail, Retail, Luxury, Home Goods, Manufacturing, Specialty, Other Manufacturing, Ibach, Interim, SVKM's NMIMS, Sleep, Wyze Labs, EVP, MBA, Nike (company), Multimedia, Kellogg School, Gap Inc., Gap, Sleep Number, Interim management, Fortune 500, CFO, Massachusetts Institute of Technology, Nike, Northwestern University, Chair, Software, Management, Pharmaceutical industry, Finance

Sleep Number Corporation (Nasdaq: SNBR), a wellness technology company, today announced the appointment of Francis Lee to Executive Vice President (EVP) and Chief Financial Officer (CFO), effective August 14, 2023.

Key Points: 
  • Sleep Number Corporation (Nasdaq: SNBR), a wellness technology company, today announced the appointment of Francis Lee to Executive Vice President (EVP) and Chief Financial Officer (CFO), effective August 14, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230727761642/en/
    Today, Sleep Number Corporation announced the appointment of Francis Lee to Executive Vice President and Chief Financial Officer, effective August 14, 2023.
  • He served as Vice President, Global Marketing Finance, a primary partner to the Chief Marketing Officer; Vice President of Finance, responsible for worldwide revenue and margin planning; and Vice President, Enterprise Strategic Investments.
  • Sleep Number also announced its second quarter 2023 earnings today, which can be found on the Sleep Number newsroom .

Two Berkshire Partners Managing Directors Selected by GrowthCap for the “Top Women Leaders in Growth Investing of 2023” Award

Retrieved on: 
Donnerstag, Juli 27, 2023
Banking, Asset Management, Professional Services, Finance, Morgan Stanley, Macalester College, Private equity, CrossFit, Kellogg School of Management, Open and Free Technology Community, Health, Partner, National Multiple Sclerosis Society, Hospital trust, Service, Woman, Boston, Multimedia, Kellogg School, Dartmouth College, TDC, McKinsey & Company, Berkshire, 4836 Medon, Payne, Investment, Committee, Harvard Business School, Berkshire Partners, Northwestern University, Female, Nursing

View the full release here: https://www.businesswire.com/news/home/20230727399757/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230727399757/en/
    Since joining Berkshire in 2000, Payne has made significant contributions to the firm and its consumer-focused investments.
  • Payne is active in various charitable activities including the National Multiple Sclerosis Society where she served as a board member.
  • “Berkshire Partners has many outstanding women leaders who Marni and I feel fortunate to work and collaborate with,” said Hoffman.
  • A fee was paid for these award entries; however, no compensation was paid in connection with the ranking or award.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Dienstag, Juli 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Dienstag, Juli 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

ESW Appoints Kelly as Co-Chairman and Eichmann as CEO at it Targets Next Phase of Growth

Retrieved on: 
Donnerstag, Juli 20, 2023
Technology, Payments, Other Retail, Security, Other Technology, Electronic Commerce, Software, Data Management, Retail, Online Retail, ESW, AOL, Senior, SVKM's NMIMS, Marketing, MBA, Kellogg School, McKinsey & Company, Commerce, LivingSocial, Spark Networks, Rosetta Stone, Growth, EPFL, Management, Fashion design, Criteo, Adolf Eichmann, Asendia, Northwestern University

Tommy Kelly, Founder and current CEO, will assume the role of Co-Chairman alongside Marc Pontet, CEO of Asendia – ESW’s owner.

Key Points: 
  • Tommy Kelly, Founder and current CEO, will assume the role of Co-Chairman alongside Marc Pontet, CEO of Asendia – ESW’s owner.
  • These appointments mark a deliberate succession plan to steer ESW towards its next phase of growth in the global ecommerce landscape.
  • In his new role as Co-Chairman, Kelly, who founded ESW in 2010, will focus on strategy and innovation, bringing his deep understanding of the industry and entrepreneurial spirit to drive ESW’s next phase of growth.
  • Kelly expressed his excitement for the transition, stating: "My time as Group CEO has been extraordinarily exciting and satisfying.

Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs

Retrieved on: 
Donnerstag, Juli 20, 2023
Gilead Sciences, University, Doctor of Philosophy, University of Illinois at Chicago, ACRV, Neoplasm, McKinsey & Company, Head, Champaign–Urbana metropolitan area, Bristol Myers Squibb, Medicine, AP3, Kellogg School, WEE1, Molecular biology, Genetics, Alexion Pharmaceuticals, Patient, PKMYT1, Therapy, Northwestern University, Pfizer, Novartis, Management

“We are thrilled to have Adam join us as a proven leader in investor relations and corporate strategy,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “We are thrilled to have Adam join us as a proven leader in investor relations and corporate strategy,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • “Adam has demonstrated a keen ability to effectively communicate novel scientific concepts and narratives in a highly cogent, constructive manner.
  • Adding Adam to the team reflects our commitment to further sharpening our communications and corporate affairs.”
    Previously, Adam served as senior vice president of investor relations at Zentalis Pharmaceuticals.
  • The company’s vision for the platform, and the therapies it can help deliver, is compelling and I look forward to being part of the team.”

Birch Lake Welcomes Joseph L. Robinson, II as Managing Director

Retrieved on: 
Donnerstag, Juli 20, 2023
Professional Services, Finance, Consulting, Asset Management, Banking, Personal Finance, SVKM's NMIMS, William Blair & Company, MBA, Multimedia, Kellogg School, Princeton University, II, Lincoln International, Growth, Northwestern University, Management, Birch Lake, Sociology

Birch Lake Holdings, LP (“Birch Lake”), a Chicago-based merchant bank that blends decades of structuring and advisory experience with principal investing, is pleased to announce Joseph L. Robinson, II has joined the firm as its newest Managing Director and member of the investment committee.

Key Points: 
  • Birch Lake Holdings, LP (“Birch Lake”), a Chicago-based merchant bank that blends decades of structuring and advisory experience with principal investing, is pleased to announce Joseph L. Robinson, II has joined the firm as its newest Managing Director and member of the investment committee.
  • View the full release here: https://www.businesswire.com/news/home/20230720979078/en/
    As Managing Director at Birch Lake, Mr. Robinson will play a key role providing strategic advice to business owners, investors, and management teams.
  • Mr. Robinson joins Birch Lake with more than 15 years of advisory experience, particularly in industrials, technology, and real estate.
  • "I am honored to join Birch Lake and work alongside such a talented team," said Mr. Robinson.